Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns
have been raised based on the notion that a considerable number of patients may have
inadequate response to clopidogrel. Although practice recommendations indicate that the use
of potent P2Y12 inhibitors (i.e., ticagrelor) may be considered in patients at increased
thrombotic risk, they do not recommend routine testing to identify patients with poor
response to clopidogrel. The aim of this study is to assess the pharmacodynamic effects of
different P2Y12 inhibiting therapy (clopidogrel vs ticagrelor) in patients at high risk for
high platelet reactivity identified according to the ABCD-GENE score in PCI treated patients
also requiring OAC. Up to a total of up to 63 patients are planned to be prospectively
enrolled in this investigation which will entail a series of comprehensive pharmacodynamic
assessments to reach the study aim.